Siltuximab vs placebo or usual care
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 1.29 [0.64, 2.62]1 study · 148 participantsLow